HRP20121019T1 - LIOFILIZIRANI PRIPRAVAK WT-1, KOJI SADRŽI CpG - Google Patents
LIOFILIZIRANI PRIPRAVAK WT-1, KOJI SADRŽI CpG Download PDFInfo
- Publication number
- HRP20121019T1 HRP20121019T1 HRP20121019AT HRP20121019T HRP20121019T1 HR P20121019 T1 HRP20121019 T1 HR P20121019T1 HR P20121019A T HRP20121019A T HR P20121019AT HR P20121019 T HRP20121019 T HR P20121019T HR P20121019 T1 HRP20121019 T1 HR P20121019T1
- Authority
- HR
- Croatia
- Prior art keywords
- immunostimulatory oligonucleotide
- seq
- preparation
- immunostimulants
- agonists
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 10
- 238000000034 method Methods 0.000 claims 10
- 238000002360 preparation method Methods 0.000 claims 8
- 108091034117 Oligonucleotide Proteins 0.000 claims 6
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 229960001438 immunostimulant agent Drugs 0.000 claims 4
- 239000003022 immunostimulating agent Substances 0.000 claims 4
- 239000000758 substrate Substances 0.000 claims 4
- 101000621309 Homo sapiens Wilms tumor protein Proteins 0.000 claims 3
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 claims 3
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims 3
- 102100022748 Wilms tumor protein Human genes 0.000 claims 3
- 108091081062 Repeated sequence (DNA) Proteins 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 229930182490 saponin Natural products 0.000 claims 2
- 150000007949 saponins Chemical class 0.000 claims 2
- 235000017709 saponins Nutrition 0.000 claims 2
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 claims 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims 1
- 102000002689 Toll-like receptor Human genes 0.000 claims 1
- 108020000411 Toll-like receptor Proteins 0.000 claims 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 239000007764 o/w emulsion Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
Claims (15)
1. Liofilizirani pripravak, naznačen time što sadrži jedan ili više antigena koji nisu pozitivno nabijeni i imunostimulacijski oligonukleotid koji sadrži CpG, gdje je navedeni jedan ili više antigena je WT-1, ili njegov derivat ili fragment, derivat je dovoljno sličan nativnim antigenima da zadrži antigena svojstva i ostane sposoban da omogući pokretanje imunosnog odgovora na WT-1, a fragment je dug najmanje 8 aminokiselina i može inducirati imunosni odgovor koji unakrsno reagira s prirodnim WT-1.
2. Pripravak u skladu s patentnim zahtjevom 1, naznačen time što navedeni imunostimulacijski oligonukleotid sadrži purin, purin, C, G, pirimidin, pirimidinski slijed.
3. Pripravak u skladu s patentni zahtjevima 1 do 2, naznačen time što se navedeni imunostimulacijski oligonukleotid bira iz skupine koju čine:
TCC ATG ACG TTC CTG ACG TT (SEQ ID NO:1);
TCT CCC AGC GTG CGC CAT (SEQ ID NO:2);
ACC GAT GAC GTC GCC GGT GAC GGC ACC ACG (SEQ ID NO: 3);
TCG TCG TTT TGT CGT TTT GTC GTT (SEQ ID NO:4);
TCC ATG ACG TTC CTG ATG CT (SEQ ID NO:5).
4. Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 ili 2, naznačen time što imunostimulacijski oligonukleotid sadrži najmanje dva nemetilirana ponovljena slijeda CG, koje razdvaja najmanje 3 nukleotida.
5. Pripravak u skladu s patentnim zahtjevom 4, naznačen time što imunostimulacijski oligonukleotid sadrži najmanje dva nemetilirana ponovljena slijeda CG, koje razdvaja 6 nukleotida.
6. Postupak dobivanja liofiliziranog pripravka u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što se sastoji u koracima miješanja željenog antigena i imunostimulacijskog oligonukleotida s pogodnim pomoćnim tvarima, te podvrgavanja dobivene formulacije liofilizacijskom ciklusu.
7. Postupak dobivanja imunogenog pripravka, naznačen time što se sastoji u koracima rekonstituiranja liofiliziranog pripravka u skladu s bilo kojim od patentnih zahtjeva 1 do 5 s pogodnom podlogom.
8. Postupak u skladu s patentnim zahtjevom 7, naznačen time što je navedena podloga partikularna podloga, koju se bira iz skupine koju čine mineralne soli, emulzije, polimeri, liposomi, ISCOM.
9. Postupak u skladu s patentnim zahtjevom 7, naznačen time što je navedena podloga liposomska otopina ili emulzija ulja u vodi.
10. Postupak u skladu s bilo kojim od patentnih zahtjeva 7 to 9, naznačen time što navedena podloga dodatno sadrži jedan ili više imunostimulansa.
11. Postupak u skladu s patentnim zahtjevom 10, naznačen time što se navedeni jedan ili više imunostimulansa bira iz skupine koju čine agonisti Toll-u sličnog receptora 4 (TLR4), antagonisti TLR 4, saponini, agonisti TLR7, agonisti TLR8, agonisti TLR9.
12. Postupak u skladu s patentnim zahtjevom 11, naznačen time što je navedeni antagonist TLR4 3-deacilirani MPL.
13. Postupak u skladu s patentnim zahtjevom 11, naznačen time što je navedeni saponin QS21.
14. Postupak u skladu s patentnim zahtjevom 10, naznačen time što navedena podloga sadrži dva imunostimulansa.
15. Postupak u skladu s patentnim zahtjevom 14, naznačen time što su navedeni imunostimulansi 3-deacilirani MPL i QS21.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2007/055037 WO2007137986A2 (en) | 2006-05-26 | 2007-05-24 | Vaccination against cancer |
GB0723044A GB0723044D0 (en) | 2007-11-23 | 2007-11-23 | Lyophillised antigen composition |
GB0723900A GB0723900D0 (en) | 2007-12-06 | 2007-12-06 | Lyophillised antigen composition |
PCT/EP2008/056305 WO2008142133A1 (en) | 2007-05-24 | 2008-05-22 | Lyophilised antigen composition |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20121019T1 true HRP20121019T1 (hr) | 2013-01-31 |
Family
ID=39714209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20121019AT HRP20121019T1 (hr) | 2007-05-24 | 2012-12-12 | LIOFILIZIRANI PRIPRAVAK WT-1, KOJI SADRŽI CpG |
Country Status (23)
Country | Link |
---|---|
US (2) | US20090035360A1 (hr) |
EP (3) | EP2148697B1 (hr) |
JP (1) | JP5331105B2 (hr) |
KR (2) | KR20110091817A (hr) |
CN (1) | CN101678091A (hr) |
AR (1) | AR066676A1 (hr) |
AU (1) | AU2008252911B2 (hr) |
BR (1) | BRPI0811228A2 (hr) |
CA (1) | CA2687632C (hr) |
CL (1) | CL2008001491A1 (hr) |
CY (1) | CY1113446T1 (hr) |
DK (1) | DK2148697T3 (hr) |
EA (3) | EA201300102A1 (hr) |
ES (1) | ES2395333T3 (hr) |
HR (1) | HRP20121019T1 (hr) |
MX (1) | MX2009012381A (hr) |
PE (1) | PE20090281A1 (hr) |
PL (1) | PL2148697T3 (hr) |
PT (1) | PT2148697E (hr) |
SI (1) | SI2148697T1 (hr) |
TW (1) | TW200911304A (hr) |
UY (1) | UY31101A1 (hr) |
WO (1) | WO2008142133A1 (hr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006110831A2 (en) | 2005-04-12 | 2006-10-19 | Duke University | Method of inducing neutralizing antibodies to human immunodeficiency virus |
CA2626238C (en) | 2005-10-17 | 2015-10-06 | Sloan Kettering Institute For Cancer Research | Wt1 hla class ii-binding peptides and compositions and methods comprising same |
ES2591029T3 (es) | 2006-04-10 | 2016-11-24 | Sloan Kettering Institute For Cancer Research | Péptidos WT-1 inmunogénicos y métodos para su uso |
CA2683752A1 (en) * | 2007-04-13 | 2008-10-23 | Duke University | Method of inducing neutralizing antibodies to human immunodeficiency virus |
EP2413951A4 (en) | 2009-04-03 | 2015-05-20 | Univ Duke | FORMULATION FOR GENERATING A WIDE REACTIVE NEUTRALIZATION OF HIV ANTIBODIES |
GB0910045D0 (en) * | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
GB0910046D0 (en) * | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
MY161412A (en) | 2010-12-14 | 2017-04-14 | Glaxosmithkline Biologicals Sa | Mycobacterium antigenic composition |
EA201391790A1 (ru) * | 2011-07-22 | 2014-06-30 | Глаксосмитклайн Байолоджикалс С.А. | Очистка prame |
AU2013207669C1 (en) | 2012-01-13 | 2018-05-31 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
PL2945647T3 (pl) | 2013-01-15 | 2021-03-08 | Memorial Sloan Kettering Cancer Center | Immunogenne peptydy wt-1 i sposoby ich zastosowania |
US10076567B2 (en) | 2013-09-27 | 2018-09-18 | Duke University | MPER-liposome conjugates and uses thereof |
EA201691348A1 (ru) * | 2013-12-31 | 2016-11-30 | Инфекшес Дизиз Рисерч Инститьют | Однофлаконные вакцинные составы |
CN106535929A (zh) * | 2014-03-25 | 2017-03-22 | 美国政府陆军部 | 增强铝盐吸附疫苗的免疫刺激效力的方法 |
SG10202012205XA (en) | 2015-11-06 | 2021-01-28 | Adjuvance Technologies Inc | Triterpene saponin analogues |
JP7136777B2 (ja) | 2016-12-07 | 2022-09-13 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 新規プロセス |
JP2020536946A (ja) * | 2017-10-16 | 2020-12-17 | アジュバンス・テクノロジーズ・インコーポレーテッド | トリテルペンサポニン類似物 |
JP7446279B2 (ja) | 2018-07-19 | 2024-03-08 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 乾燥多糖を調製するための方法 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5827A (en) | 1848-10-03 | Improved table-cutlery | ||
US666A (en) | 1838-04-02 | Sfbing-bock for coagh and railroad-gab | ||
US6222020B1 (en) | 1987-01-07 | 2001-04-24 | Imperial Cancer Research Technology Limited | Antigens derived from the core protein of the human mammary epithelial mucin |
JPH02501828A (ja) | 1987-01-07 | 1990-06-21 | インペリアル・キヤンサー・リサーチ・テクノロジー・リミテツド | プローブ |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4963484A (en) * | 1988-01-29 | 1990-10-16 | Dana-Farber Cancer Institute, Inc. | Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen |
US5278302A (en) * | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US4912094B1 (en) * | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
US5256643A (en) * | 1990-05-29 | 1993-10-26 | The Government Of The United States | Human cripto protein |
SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
US5744144A (en) * | 1993-07-30 | 1998-04-28 | University Of Pittsburgh University Patent Committee Policy And Procedures | Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof |
US5688506A (en) | 1994-01-27 | 1997-11-18 | Aphton Corp. | Immunogens against gonadotropin releasing hormone |
WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
CA2194761C (en) | 1994-07-15 | 2006-12-19 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US5830753A (en) | 1994-09-30 | 1998-11-03 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof. |
US5981215A (en) * | 1995-06-06 | 1999-11-09 | Human Genome Sciences, Inc. | Human criptin growth factor |
US5666153A (en) | 1995-10-03 | 1997-09-09 | Virtual Shopping, Inc. | Retractable teleconferencing apparatus |
WO1998050567A1 (en) | 1997-05-02 | 1998-11-12 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
JP2001517638A (ja) * | 1997-09-25 | 2001-10-09 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | 小細胞肺癌に対するフコーシルgm−1−klh接合体ワクチン |
GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
JP2002518048A (ja) | 1998-06-22 | 2002-06-25 | インサイト・ファーマスーティカルズ・インコーポレイテッド | 前立腺癌関連遺伝子 |
JP4620251B2 (ja) * | 1998-08-10 | 2011-01-26 | アンチジェニックス・インコーポレイテッド | Cpgおよびサポニンアジュバントの組成物並びにその方法 |
US20030235557A1 (en) * | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
CA2361009C (en) | 1999-01-29 | 2012-10-23 | Corixa Corporation | Her-2/neu fusion proteins |
PT1165778E (pt) | 1999-03-11 | 2007-01-31 | Glaxosmithkline Biolog Sa | Utilizações de polinucleótidos e polipéptidos casb618 |
US6949520B1 (en) * | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
IL151097A0 (en) | 2000-02-23 | 2003-04-10 | Smithkline Beecham Biolog | Tumour-specific animal proteins |
US20040022814A1 (en) * | 2000-06-15 | 2004-02-05 | O'hagan Derek | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
GB0022742D0 (en) * | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
WO2002026757A2 (en) | 2000-09-26 | 2002-04-04 | Hybridon, Inc. | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
US20030031684A1 (en) | 2001-03-30 | 2003-02-13 | Corixa Corporation | Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA) |
US7553494B2 (en) * | 2001-08-24 | 2009-06-30 | Corixa Corporation | WT1 fusion proteins |
HUP0402259A3 (en) | 2001-09-20 | 2010-01-28 | Glaxo Group Ltd | Vaccines |
WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
GB0218821D0 (en) * | 2002-08-13 | 2002-09-18 | Glaxosmithkline Biolog Sa | Novel compositions |
JP2006512097A (ja) * | 2002-12-23 | 2006-04-13 | シティ・オブ・ホープ | 癌免疫療法におけるp53を発現する改変・ワクシニア・アンカラ |
GB0323968D0 (en) | 2003-10-13 | 2003-11-19 | Glaxosmithkline Biolog Sa | Immunogenic compositions |
EP1547581A1 (en) * | 2003-12-23 | 2005-06-29 | Vectron Therapeutics AG | Liposomal vaccine for the treatment of human hematological malignancies |
GB0409940D0 (en) * | 2004-05-04 | 2004-06-09 | Glaxosmithkline Biolog Sa | Vaccine |
GB0411411D0 (en) | 2004-05-21 | 2004-06-23 | Glaxosmithkline Biolog Sa | Vaccines |
WO2005123112A2 (en) * | 2004-06-12 | 2005-12-29 | Pharma Pacific Pty Ltd. | Method of enhancing the immune response to a vaccine |
GB0417494D0 (en) | 2004-08-05 | 2004-09-08 | Glaxosmithkline Biolog Sa | Vaccine |
WO2006092017A1 (en) | 2005-03-02 | 2006-09-08 | Solbec Pharmaceuticals Limited | Glycoalkaloid and tlr agonist combinations and various uses thereof |
SG162817A1 (en) * | 2005-06-17 | 2010-07-29 | Mannkind Corp | Methods and compositions.to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma |
-
2008
- 2008-05-22 CA CA2687632A patent/CA2687632C/en not_active Expired - Fee Related
- 2008-05-22 TW TW097119008A patent/TW200911304A/zh unknown
- 2008-05-22 WO PCT/EP2008/056305 patent/WO2008142133A1/en active Application Filing
- 2008-05-22 KR KR1020117016237A patent/KR20110091817A/ko not_active Application Discontinuation
- 2008-05-22 KR KR1020097025005A patent/KR101238795B1/ko not_active IP Right Cessation
- 2008-05-22 EA EA201300102A patent/EA201300102A1/ru unknown
- 2008-05-22 AR ARP080102167A patent/AR066676A1/es not_active Application Discontinuation
- 2008-05-22 EA EA200901434A patent/EA018201B1/ru not_active IP Right Cessation
- 2008-05-22 SI SI200830836T patent/SI2148697T1/sl unknown
- 2008-05-22 MX MX2009012381A patent/MX2009012381A/es active IP Right Grant
- 2008-05-22 BR BRPI0811228-2A2A patent/BRPI0811228A2/pt not_active IP Right Cessation
- 2008-05-22 CL CL2008001491A patent/CL2008001491A1/es unknown
- 2008-05-22 UY UY31101A patent/UY31101A1/es unknown
- 2008-05-22 EP EP08759906A patent/EP2148697B1/en not_active Not-in-force
- 2008-05-22 AU AU2008252911A patent/AU2008252911B2/en not_active Ceased
- 2008-05-22 US US12/125,182 patent/US20090035360A1/en not_active Abandoned
- 2008-05-22 PE PE2008000879A patent/PE20090281A1/es not_active Application Discontinuation
- 2008-05-22 PT PT87599064T patent/PT2148697E/pt unknown
- 2008-05-22 PL PL08759906T patent/PL2148697T3/pl unknown
- 2008-05-22 CN CN200880017245A patent/CN101678091A/zh active Pending
- 2008-05-22 EP EP12157796A patent/EP2476431A1/en not_active Withdrawn
- 2008-05-22 DK DK08759906.4T patent/DK2148697T3/da active
- 2008-05-22 EA EA201300101A patent/EA201300101A1/ru unknown
- 2008-05-22 JP JP2010508850A patent/JP5331105B2/ja not_active Expired - Fee Related
- 2008-05-22 EP EP20120157797 patent/EP2489367A1/en not_active Withdrawn
- 2008-05-22 ES ES08759906T patent/ES2395333T3/es active Active
-
2010
- 2010-11-15 US US12/946,171 patent/US8557247B2/en not_active Expired - Fee Related
-
2012
- 2012-12-10 CY CY20121101196T patent/CY1113446T1/el unknown
- 2012-12-12 HR HRP20121019AT patent/HRP20121019T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20121019T1 (hr) | LIOFILIZIRANI PRIPRAVAK WT-1, KOJI SADRŽI CpG | |
Shi et al. | Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity | |
Krishnamachari et al. | Innovative strategies for co-delivering antigens and CpG oligonucleotides | |
Siefert et al. | Artificial bacterial biomimetic nanoparticles synergize pathogen-associated molecular patterns for vaccine efficacy | |
Garçon et al. | Vaccine adjuvants | |
Dey et al. | Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens | |
JP5769624B2 (ja) | ワクチン | |
JP5749642B2 (ja) | ワクチン | |
RU2009144125A (ru) | Виросомы, содержащие гемагглютинин, полученный из вируса гриппа, вырабатываемого в клеточной линии; композиции, методы получения и применение на их основе | |
CN1980691A (zh) | 用于癌症免疫疗法的基于mage-3和ny-eso-1的多价疫苗 | |
SI2468300T1 (en) | A vaccine composition comprising a synthetic adjuvant | |
Kenney et al. | Adjuvants for the future | |
US20110189223A1 (en) | Vaccine | |
Lodaya et al. | Overview of vaccine adjuvants | |
RU2005102589A (ru) | Антигенные композиции | |
US20230061403A1 (en) | Shingles vaccines comprising a tlr9 agonist | |
CN107847603B (zh) | 脂质体佐剂组合物 | |
Garçon et al. | Evolution of adjuvants across | |
Yang et al. | Montmorillonite nanosheets as an adjuvant eliciting potent cellular immunity | |
Goetz et al. | Vaccine adjuvants for infectious disease in the clinic | |
Wilson-welder | In vitro and in vivo evaluation of novel biodegradable polymer adjuvants for vaccine delivery | |
Fox et al. | Enhancing and tailoring the immunogenicity of vaccines with novel adjuvants |